These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 35603186)

  • 1. Overcoming Immune Resistance With Radiation Therapy in Prostate Cancer.
    Mulvey A; Muggeo-Bertin E; Berthold DR; Herrera FG
    Front Immunol; 2022; 13():859785. PubMed ID: 35603186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment.
    Sun BL
    Prostate; 2021 Nov; 81(15):1125-1134. PubMed ID: 34435699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy in Prostate Cancer: State of Art and New Therapeutic Perspectives.
    Maselli FM; Giuliani F; Laface C; Perrone M; Melaccio A; De Santis P; Santoro AN; Guarini C; Iaia ML; Fedele P
    Curr Oncol; 2023 Jun; 30(6):5769-5794. PubMed ID: 37366915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Updated studies on the immunotherapy of prostate cancer].
    Liu J; Li WP; Yang SJ
    Zhonghua Nan Ke Xue; 2022 Apr; 28(4):349-355. PubMed ID: 37477458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current Status and Future Perspectives of Checkpoint Inhibitor Immunotherapy for Prostate Cancer: A Comprehensive Review.
    Kim TJ; Koo KC
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen deprivation and immunotherapy for the treatment of prostate cancer.
    Gamat M; McNeel DG
    Endocr Relat Cancer; 2017 Dec; 24(12):T297-T310. PubMed ID: 28814451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy?
    Heidegger I; Necchi A; Pircher A; Tsaur I; Marra G; Kasivisvanathan V; Kretschmer A; Mathieu R; Ceci F; van den Bergh RCN; Thibault C; Tilki D; Valerio M; Surcel C; Gandaglia G;
    Eur Urol Oncol; 2021 Oct; 4(5):745-754. PubMed ID: 33243663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in and prospects of immunotherapy for prostate cancer.
    Liu D; Wang L; Guo Y
    Cancer Lett; 2024 Oct; 601():217155. PubMed ID: 39127338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
    Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
    Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current management of advanced and castration resistant prostate cancer.
    Gomella LG; Petrylak DP; Shayegan B
    Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological Complexity of the Prostate Cancer Microenvironment Influences the Response to Immunotherapy.
    Prokhnevska N; Emerson DA; Kissick HT; Redmond WL
    Adv Exp Med Biol; 2019; 1210():121-147. PubMed ID: 31900908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer.
    Stultz J; Fong L
    Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):697-717. PubMed ID: 33820953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance.
    Alberti C
    G Chir; 2017; 37(5):225-235. PubMed ID: 28098061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate Cancer Immunotherapy-Finally in From the Cold?
    Runcie KD; Dallos MC
    Curr Oncol Rep; 2021 Jun; 23(8):88. PubMed ID: 34125308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequencing systemic therapies in metastatic castration-resistant prostate cancer.
    Liu JJ; Zhang J
    Cancer Control; 2013 Jul; 20(3):181-7. PubMed ID: 23811702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Moving toward improved immune checkpoint immunotherapy for advanced prostate cancer.
    De Velasco MA; Kura Y; Fujita K; Uemura H
    Int J Urol; 2024 Apr; 31(4):307-324. PubMed ID: 38167824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of radiotherapy on bone metastases from prostate adenocarcinoma: What is the future for the combination with radiotherapy/immunotherapy?
    Cornillon P; Bouleftour W; Reynaud T; Pigne G; Maillet D; Hamizi S; Beguinot M
    Tumori; 2024 Oct; 110(5):319-326. PubMed ID: 38745528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor immune contexture predicts recurrence after prostatectomy and efficacy of androgen deprivation and immunotherapy in prostate cancer.
    Han S; Shi T; Liao Y; Chen D; Yang F; Wang M; Ma J; Li H; Xu Y; Zhu T; Chen W; Wang G; Han Y; Xu C; Wang W; Cai S; Zhang X; Xing N
    J Transl Med; 2023 Mar; 21(1):194. PubMed ID: 36918939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The evolving landscape of immunotherapy in advanced prostate cancer.
    Patel VG; Oh WK
    Immunotherapy; 2019 Jul; 11(10):903-912. PubMed ID: 31161846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer.
    Rathi N; McFarland TR; Nussenzveig R; Agarwal N; Swami U
    Drugs; 2021 Feb; 81(2):191-206. PubMed ID: 33369720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.